Cyclerion Therapeutics Inc. has announced a strategic collaboration with Medsteer SAS to advance the development of its closed-loop anesthetic platform. The partnership grants Cyclerion access to Medsteer's proprietary EEG-guided closed-loop control technology, including computational modules, control software, and extensive clinical datasets. This collaboration aims to accelerate the integration of Medsteer's technology into Cyclerion's lead program, CYC-126, which targets treatment-resistant depression. The combined expertise will support the completion of device integration and the initiation of a Phase 2 proof-of-concept study in the second half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cyclerion Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9620077-en) on January 05, 2026, and is solely responsible for the information contained therein.